CervoMed to Present at the 8th International Lewy Body Dementia Conference
CervoMed Inc. (CRVO)
Company Research
Source: GlobeNewswire
BOSTON, Jan. 29, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced that topline results from the Phase 2b RewinD-LB study will be presented at the 8th International Lewy Body Dementia Conference (ILBDC), being held in Amsterdam, on January 31, 2025. The initial topline results for the Phase 2b study of neflamapimod in dementia with Lewy bodies (DLB) were previously disclosed on December 10, 2024 and are available here. Details of the ILBDC presentation are as follow: Abstract Title: Efficacy and safety results of the RewinD-LB phase 2b clinical trial of neflamapimod in dementia with Lewy bodies (DLB)Format: Oral PresentationPresenter: John Alam, MD, CEO of CervoMed and Co-Principal Investigator of the RewinD-LB StudySession Name: Symposium VIII-TherapySession Date and Time: Friday, January 31, 2025, 13:30pm CET / 7:30am ET The details of the presentation will be ac
Show less
Read more
Impact Snapshot
Event Time:
CRVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CRVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CRVO alerts
High impacting CervoMed Inc. news events
Weekly update
A roundup of the hottest topics
CRVO
News
- CervoMed Announces Late-Breaking Data at the 18th CTAD Conference Demonstrating Neflamapimod Significantly Slows Clinical Progression in Dementia with Lewy BodiesGlobeNewswire
- CervoMed (NASDAQ:CRVO) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $31.00 price target on the stock.MarketBeat
- CervoMed Presents New Plasma Biomarker Data That Indicates Neflamapimod Broadly Improves Neuroinflammation and Neurodegeneration in Dementia with Lewy Bodies (DLB)GlobeNewswire
- CervoMed to Share New Data on Neflamapimod as a Treatment for Dementia with Lewy Bodies at the 18th Clinical Trials on Alzheimer's Disease (CTAD) ConferenceGlobeNewswire
- CervoMed (NASDAQ:CRVO) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $31.00 price target on the stock.MarketBeat
CRVO
Earnings
- 11/7/25 - Miss
CRVO
Sec Filings
- 12/5/25 - Form 4
- 12/5/25 - Form 3
- 12/5/25 - Form 8-K
- CRVO's page on the SEC website